Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 25;18(2):244.
doi: 10.3390/ijms18020244.

Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action

Tae-Hoon Shin  1   2 , Hyung-Sik Kim  3   4 , Soon Won Choi  5   6 , Kyung-Sun Kang  7   8
Affiliations
Review

Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action

Tae-Hoon Shin et al. Int J Mol Sci. .

Abstract

Inflammatory skin disorders that cause serious deterioration of the quality of life have become one of the major public concerns. Despite their significance, there is no fundamental cure to date. Mesenchymal stem cells (MSCs) possess unique immunomodulatory properties which make them a promising tool for the treatment of various inflammatory diseases. Our recent preclinical and clinical studies have shown that MSCs can be successfully used for the treatment of atopic dermatitis (AD), one of the major inflammatory skin diseases. This observation along with similar reports from other groups revealed the efficacy and underlying mechanisms of MSCs in inflammatory dermatosis. In addition, it has been proposed that cell priming or gene transduction can be novel strategies for the development of next-generation high-efficacy MSCs for treating inflammatory skin diseases. We discuss here existing evidence that demonstrates the regulatory properties of MSCs on immune responses under inflammatory conditions.

Keywords: atopic dermatitis; immunomodulation; inflammatory skin diseases; mesenchymal stem cells; psoriasis; stem cell therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of MSC immunomodulation against principal inflammation-aggravating immune cells within inflammatory skin conditions. Red line: suppressive effect; Blue arrow: stimulatory effect.
See this image and copyright information in PMC

References

    1. Odhiambo J.A., Williams H.C., Clayton T.O., Robertson C.F., Asher M.I., ISAAC Phase Three Study Group Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J. Allergy Clin. Immunol. 2009;124:1251–1258. doi: 10.1016/j.jaci.2009.10.009. - DOI - PubMed
    1. Silverberg J.I., Hanifin J.M. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. J. Allergy Clin. Immunol. 2013;132:1132–1138. doi: 10.1016/j.jaci.2013.08.031. - DOI - PubMed
    1. Williams H., Flohr C. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J. Allergy Clin. Immunol. 2006;118:209–213. doi: 10.1016/j.jaci.2006.04.043. - DOI - PubMed
    1. Chehregani A., Majde A., Moin M., Gholami M., Shariatzadeh M.A., Nassiri H. Increasing allergy potency of Zinnia pollen grains in polluted areas. Ecotoxicol. Environ. Saf. 2004;58:267–272. doi: 10.1016/j.ecoenv.2003.12.004. - DOI - PubMed
    1. Diaz-Sanchez D., Penichet-Garcia M., Saxon A. Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity. J. Allergy Clin. Immunol. 2000;106:1140–1146. doi: 10.1067/mai.2000.111144. - DOI - PubMed

MeSH terms

LinkOut - more resources